论文部分内容阅读
初发T2DM患者100例,随机分为对照组和治疗组各50例。治疗组予那格列奈(唐力)联合甘精胰岛素(来得时)治疗,对照组予阿卡波糖(拜唐苹)联合甘精胰岛素治疗,疗程16周。治疗前后均做空腹、30、60、120、180分钟胰岛素测定。通过早相分泌指数(△I30/△G30,糖负荷后30分钟胰岛素浓度与血浆葡萄糖浓度的比值)评估胰岛B细胞早时相胰岛素分泌能力。结论:那格列奈能改善初发T2DM患者早时相胰岛素分泌。
100 cases of newly diagnosed T2DM patients were randomly divided into control group and treatment group, 50 cases each. The treatment group was treated with nateglinide (Tang Li) combined with insulin glargine (when) treatment, the control group to acarbose (Baitang Ping) combined with insulin glargine treatment for 16 weeks. Fasting before and after treatment, 30,60,120,180 minutes insulin test. The early phase insulin secretion ability of pancreatic B cells was evaluated by the early phase secretion index (? I30 /? G30, the ratio of the 30-minute insulin concentration to the plasma glucose concentration after the glucose load). Conclusion: Nateglinide can improve early phase insulin secretion in newly diagnosed T2DM patients.